Analysis of EGFR mutation frequency and coexistence of KRAS and EGFR mutations using RT-PCR in lung adenocarcinoma: May a clinical and pathological model of a patient's qualification for targeted therapy have an impact on time to obtain genetic results?;Ocena czȩstości wystȩpowania mutacji w genie EGFR i współwystȩpowania mutacji EGFR i KRAS metoda̧ reakcji łańcuchowej polimerazy w czasie rzeczywistym u chorych na raka gruczolowego pluca - czy kliniczno-patologiczny model kwalifikacji pacjenta do leczenia celowanego moze miec wpyw na czas uzyskania wyniku genetycznego?

Kardiochirurgia i Torakochirurgia Polska

Volumn 9, Issue 4, 2012, Pages 443-451

  Lewandowska, Marzena Anna ^a,b   Jóźwicki, Wojciech ^a,b   Starzyński, Jarosław ^a   Kowalewski, Janusz ^a,b  

^a Regional Oncology Centre Bydgoszcz   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

EGFR; NSCLC; Personalized oncology; Targeted therapy

Indexed keywords

EID: 84874234453     PISSN: 17315530     EISSN: None     Source Type: Journal    
DOI: 10.5114/kitp.2012.32682     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, Nukiwa T, Miyaoka E. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. Journal of Thoracic Oncology: official publication of the International Association for the Study of Lung Cancer 2008; 3: 46-52.
3. Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 2001; 71: 1759-1764.
4. Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg 2001; 122: 548-553.
5. Tanvetyanon T, Robinson LA, Schell MJ, Strong VE, Kapoor R, Coit DG, Bepler G. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology 2008; 26: 1142-1147.
6. Cakir S, Egehan I. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 2004; 43: 309-316.
7. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R. Cisplatinversus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. Journal of the National Cancer Institute 2007; 99: 847-857.
8. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology 2005; 23: 857-865.
9. Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol 2005; 70: 419-426.
10. Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer 2011; 104: 316-323.
11. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P, Vlachonikolis I. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357: 1478-1484.
12. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England journal of medicine 2010; 362: 2380-2388.
13. Barlesi F, Nanni-Metellus I, Breen D, Fina F, Astoul P, Martin PM. Non-small cell lung cancer-smokers or non-smokers, does it matter? Lung Cancer 2009; 63: 430-432.
14. Wu JY, Shih JY, Yang CH, Chen KY, Ho CC, Yu CJ, Yang PC. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. International Journal of Cancer Journal International du Cancer 2010; 126: 247-255.
15. Travis WD, Rekhtman N, Riley GJ, Geisinger KR, Asamura H, Brambilla E, Garg K, Hirsch FR, Noguchi M, Powell CA, Rusch VW, Scagliotti G, Yatabe Y. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2010; 5: 411-414.
16. Garcia-Olive I, Monso E, Andreo F, Sanz-Santos J, Taron M, Molina-Vila MA, Llatjos M, Castella E, Moran T, Bertran-Alamillo J, Mayo-de-Las-Casas C, Queralt C, Rosell R. Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J 2010; 35: 391-395.
17. Felip E, Gridelli C, Baas P, Rosell R, Stahel R. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2011; 22: 1507-1519.
18. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
19. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-1167.
20. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. The Journal of molecular diagnostics: JMD 2010; 12: 169-176.
21. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
22. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010; 28: 4769-4777.
23. Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Brambilla E, Hainaut P. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer research 2007; 67: 5667-5672.
24. Choi H, Kratz J, Pham P, Lee S, Ray R, Kwon YW, Mao JH, Kang HC, Jablons D, Kim IJ. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma. International journal of oncology 2012; 40: 1900-1906.
25. Lewandowska MA, Jóźwicki W, Zurawski B, Starzyński J, Rhone P. Can we believe in CE-IVD tests for KRAS mutation analysis? Oncology as a challenge for modern medicine. Piaszczyk D (ed.). PSW, Biała Podlaska 2012, pp. 87-99.